SARS-CoV-2 VLP aşısına karşı geliştirilen hümoral ve hücresel immün yanıtların klinik öncesi ve klinik çalışmalarda incelenmesi

COVID-19 pandemic, caused by SARS-CoV-2, emerged in China in late 2019, and as of March 2020 has become a serious concern for the whole world due to severe progression of the disease especially in the elderly and high transmission rate of the virus. The ravages of pandemic on health sector, economy and social life accelerated the vaccine race as vaccination is the most critical measure to hamper the pace of the pandemic and the most important step for acquiring herd immunity. Various vaccine studies are registered by WHO most of which target Spike protein or a certain region of Spike protein, such as receptor binding domain (RBD) for inducing immune reactions. Alternatively, the use of virus-like particle (VLP) technology for vaccine development broadens the magnitude of immune responses as the four main structural proteins of the virus, Spike, Nucleocapsid, Membrane and Envelope, are incorporated. Therefore, we developed a VLP vaccine against SARS-CoV-2 and adjuvanted it using Alum and K3 CpG ODN. Herein, we investigated the humoral and cellular immune responses induced by SARS-CoV-2 VLP vaccine in pre-clinical and clinical studies. The results from pre-clinical experiments conducted on vaccinated BALB/c mice indicated that VLP vaccine triggered effective antibody response against Spike, Nucleocapsid, Wild Type RBD, Alpha RBD and Delta RBD proteins as shown by ELISA. Additionally, it was proven that the diminishing antibody responses can be boosted and a prolonged immune response was achieved by a third dose of VLP vaccine. For the clinical studies, the humoral and cellular immune responses of Phase II clinical trial volunteers were analyzed by employing ELISA and CBA methods respectively. The results obtained from ELISA demonstrated that the Phase II volunteers developed effective antibody titers against Spike, Nucleocapsid, Wild Type RBD, Alpha RBD and Delta RBD proteins. Analysis of the cellular immune responses by CBA showed that VLP vaccine induced a Th1-skewed immune reaction with coexistence of Th2-, Th17- and Treg related responses owing to its formulation with K3 CpG ODN and Alum. Taken together, our results indicated that SARS-CoV-2 VLP vaccine triggered effective cellular and humoral immune reactions against Spike and Nucleocapsid along with RBD variants which proved the cross-protective response achieved. Elicitation of multi-functional immune response and adoptability of the VLP technology to newly emerging variants makes VLP vaccine a promising candidate for the future booster injections.